Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21787242 | 0.85 | SMYD3 (0.49) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL19662620 | 0.83 | GRIN1 (0.47) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL21787244 | 0.81 | HDAC1 (0.47) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL21787243 | 0.81 | MAPK1 (0.50) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL19662501 | 0.80 | HDAC1 (0.49) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL29855708 | 0.75 | HDAC6 (0.53) | HDAC6MAPK1 | |
| SCHEMBL24440484 | 0.74 | HDAC6 (0.60) | HDAC6 | |
| SCHEMBL29633482 | 0.74 | HDAC6 (0.60) | HDAC6 | |
| SCHEMBL18619400 | 0.73 | HDAC6 (0.58) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL24913445 | 0.72 | HDAC6 (0.53) | HDAC6HDAC1HDAC2HDAC8MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-26 | — | — | US | disclosed |
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, RNGTT | HDAC6 3868/4885HDAC1 4732/4885HDAC3 4156/4885 |
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, NUDT1 | HDAC6 4002/4885HDAC1 4822/4885HDAC3 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.